Track market-moving stories before they get noisy

Trump Index: 6 Companies Linked to Trump’s Cabinet Worth WatchingRoivant Sciences NASDAQ: ROIV executives used the company’s fourth-quarter earnings call to highlight new open-label data for IMVT-1402 in difficult-to-treat rheumatoid arthritis, upcoming pulmonary hypertension data for mosliciguat and continued preparation for a potential brepocitinib launch in dermatomyositis.

Chief Executive Matt Gline called the company’s recent period “a pretty wild 12 months,” citing progress across development programs and the previously announced $2.25 billion settlement with Moderna. Gline said Roivant expects to receive the first $950 million upfront portion of that settlement in July.

Get Roivant Sciences alerts:

IMVT-1402 Shows Open-Label Activity in Refractory RA The most prominent update centered on preliminary data from the open-label portion of the 1402 study in difficult-to-treat rheumatoid arthritis, or D2T RA. Gline described the results as “surprisingly good,” while cautioning that the data came from an open-label phase of the trial.

The study enrolled heavily refractory patients who had failed steroids and DMARDs as well as at least two advanced lines of therapy. Gline said 65% of patients had failed JAK inhibitors, and that “basically every single one” of those patients had also failed a TNF inhibitor. The study also required autoantibody positivity using ACPA criteria.

In the preliminary period 1 data, Roivant reported that roughly 73% of evaluable patients achieved an ACR20 response. More than half achieved ACR50, and more than one-third achieved ACR70. Gline said the depth of response was especially notable because placebo responses are less common at the ACR50 and ACR70 levels.

“It feels to us like looking at this data, there’s something going on that’s meaningful and interesting with this drug,” Gline said.

Gline said the responses were “basically fully preserved” in the subset of patients who had prior JAK inhibitor exposure, a group he characterized as both JAK- and TNF-experienced. He said the findings support the biological thesis that ACPA positivity may represent a mechanism distinct from other anti-inflammatory approaches.

The randomized withdrawal portion of the study is still ongoing. Gline said more than half of patients remain on study treatment, and the company does not yet have data from period 2. He also noted that period 2 may be harder to interpret because patients with deep ACR50 or ACR70 responses may take time to lose an ACR20 response after withdrawal.

Roivant expects to share additional analysis, including patient-level data and feedback from discussions with the U.S. Food and Drug Administration, in the second half of the year. Gline said the company is preparing to discuss the data with regulators and hopes to outline next steps for the program.

Mosliciguat Data Expected in Second Half Roivant also provided a detailed preview of mosliciguat, an inhaled soluble guanylate cyclase, or sGC, activator being studied in pulmonary hypertension associated with interstitial lung disease, or PH-ILD. Drew Fromkin, CEO of Pulmovant, said mosliciguat is designed to activate sGC directly in the lungs and potentially address both pulmonary vascular disease and lung parenchymal disease.

Fromkin said Bayer previously studied mosliciguat in 170 participants, including healthy volunteers and pulmonary hypertension patients, before Roivant’s program advanced into PH-ILD. In phase I-B data, he said a single dose produced a mean pulmonary vascular resistance reduction of more than 30% and a mean peak reduction of about 38%. He also said the drug was well-tolerated, with mild to moderate treatment-emergent adverse events and no clinically meaningful systemic blood pressure or heart rate effects.

The ongoing PHocus phase II study enrolled 135 patients, above its target of 120. Fromkin said more than 95% of participants reached and sustained the 4-milligram dose through week 16. The primary endpoint is change from baseline in pulmonary vascular resistance at week 16, with secondary measures including six-minute walk distance and NT-proBNP.

Gline emphasized that the study is not powered to show a statistically significant benefit on six-minute walk distance. He said Roivant is primarily looking for confirmation of dosing, safety and pulmonary vascular resistance effects in the patient population.

Brepocitinib Launch Preparation Continues Roivant also updated investors on brepocitinib, which Gline said could potentially launch in dermatomyositis by the end of September if the FDA review proceeds as expected. He said the company is engaged in payer discussions, physician outreach, specialty pharmacy partnerships and unbranded patient engagement.

Gline said brepocitinib was awarded breakthrough therapy designation and rare therapy designation for cutaneous sarcoidosis. Roivant expects a phase III study in cutaneous sarcoidosis to begin this year. The company also recently announced lichen planopilaris, or LPP, as a fourth indication for brepocitinib, and Gline said that study is already enrolling.

For dermatomyositis, Gline described a high unmet need, noting that many patients rely on steroids, IVIG or off-label therapies. He said phase III brepocitinib data were published in the New England Journal of Medicine in March, which he called a testament to the importance and quality of the study.

Financial Position and Upcoming Milestones Gline said Roivant ended March 31 with $4.3 billion in cash and equivalents, before receipt of the Moderna settlement payment, and no debt. He also said the company continued to retire shares during the quarter.

Key milestones discussed on the call include:

Potential brepocitinib launch in dermatomyositis by the end of September, pending FDA action. Phase III top-line data in noninfectious uveitis expected in the second half of the year. Mosliciguat phase II-B top-line data in PH-ILD expected in the second half of 2026. Additional IMVT-1402 analysis in D2T RA, including FDA feedback, expected in the second half. IMVT-1402 data in Graves’ disease and myasthenia gravis expected in 2027. Gline said Roivant’s portfolio has “as much in the windshield as in the rearview mirror,” pointing to multiple data readouts and potential commercial activities ahead.

About Roivant Sciences NASDAQ: ROIVRoivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in Roivant Sciences Right Now?Before you consider Roivant Sciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roivant Sciences wasn't on the list.

While Roivant Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Roivant (ROIV) remains a Buy as its unique 'vant' structure rapidly advances and monetizes blockbuster assets, notably through Immunovant's IMVT-1402 in rheumatoid arthritis. IMVT-1402 delivered strong Phase 2 efficacy in difficult-to-treat rheumatoid arthritis, with ACR20/50/70 rates of 72.7%, 54.5%, and 35.8%, respectively. ROIV's financial position is robust, ending the quarter with $4.3 billion in cash and a management-asserted runway to profitability.

Roivant Sciences Ltd. (ROIV) Presents at Jefferies Global Healthcare Conference 2026 Transcript

April 27, 2026 16:01 ET  | Source: Intellia Therapeutics, Inc.

CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that it has commenced an underwritten public offering of $150 million of shares of its common stock. Intellia also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the public offering. All of the shares in the proposed offering are to be sold by Intellia.

Jefferies, Goldman Sachs & Co. LLC and Citigroup are acting as joint book-running managers for the proposed offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

The shares of common stock are being offered by Intellia pursuant to an automatic shelf registration statement on Form S-3ASR (File No. 333-275740) that was previously filed with the U.S. Securities and Exchange Commission (SEC) on November 24, 2023 and automatically became effective upon filing. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the offering will be filed with the SEC and may be obtained, when available, from: Jefferies LLC, by mail at Attn: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at [email protected]; Goldman Sachs & Co. LLC, by mail at Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at (866) 471-2526, or by email at [email protected]; or Citigroup, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 (Tel: 800-831-9146).

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Intellia Therapeutics
Intellia Therapeutics, Inc. (Nasdaq: NTLA) is a leading clinical-stage biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. The company’s mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, Intellia aims to reset the standard for medicine by durably treating the root causes of disease.

Forward-Looking Statements
This press release contains “forward-looking statements” of Intellia Therapeutics, Inc. (“Intellia” or the “Company”) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding Intellia’s beliefs and expectations regarding the proposed public offering; uncertainties related to market conditions and statements regarding the timing, size and expected proceeds of the proposed public offering; the safety, tolerability, efficacy, advancement and success of Intellia’s clinical programs; and Intellia’s ability to successfully execute its business and strategic plans, including the advancement, development and commercialization of its product candidates.

Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: risks related to Intellia’s ability to protect and maintain its intellectual property position; risks related to valid third party intellectual property; risks related to Intellia’s relationship with third parties, including its licensors and licensees; risks related to the ability of its licensors to protect and maintain their intellectual property position; uncertainties related to regulatory agencies’ evaluation of regulatory filings and other information related to our product candidates, including nex-z; uncertainties related to the authorization, initiation and conduct of studies and other development requirements for our product candidates, including uncertainties related to regulatory approvals to conduct clinical trials; the risk that any one or more of Intellia’s product candidates will not be successfully developed and commercialized; the risk that the results of preclinical studies or clinical studies will not be predictive of future results in connection with future studies for the same product candidate or Intellia’s other product candidates; and risks related to Intellia’s reliance on collaborations, including that its collaboration with Regeneron Pharmaceuticals, Inc. will not continue or will not be successful. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Intellia’s actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in Intellia’s most recent annual report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in Intellia’s other filings with the Securities and Exchange Commission, including its quarterly reports on Form 10-Q. All information in this press release is as of the date of the release, and Intellia undertakes no duty to update this information unless required by law.

Investor Contact:
Jason Fredette
Vice President, Investor Relations and Corporate Communications
Intellia Therapeutics, Inc.
[email protected]

Media Contact:
Mike Tattory
Vice President
LifeSci Communications
[email protected]

While the heyday of Cathie Wood’s investment management is, for the time being, firmly in the past, the popular ARK Innovation ETF (ARKK) has been having a respectable run in the last 12 months and unveiled its latest series of bets as recently as April 28.

ARKK ETF one-year price chart. Source: Google Specifically, ARKK revealed on Tuesday that it invested a total of nearly $42 million in four stocks: Alphabet (NASDAQ: GOOG), CoreWeave (NASDAQ: CRWV), Intellia Therapeutics (NASDAQ: NTLA), and Kratos Defense & Security Solutions (NASDAQ: KTOS).

The purchases of NTLA and KTOS shares ranged between $6 and $6.9 million, and together, the two account for just 0.13% of the exchange-traded fund (ETF).

Simultaneously, the market value of the April 28 Google stock investment is listed at $14.1 million – 0.14% of the ETF – and in CoreWeave at $14.8 million – 0.15%.

ARKK ETF April 28 investments. Source: Cathie’s Ark Cathie Wood invests $14.8 million in CoreWeave stock Elsewhere, the timing of the two bigger investments is interesting for a variety of reasons. CoreWeave is, as a company, seen as either a firm that is doomed to collapse or one of the most exciting investment opportunities of 2026.

Indeed, the former cryptocurrency miner made a pivot to becoming an artificial intelligence (AI) data center, securing backing from the semiconductor giant Nvidia (NASDAQ: NVDA). 

Under the circumstances, Cathie Wood appears to be betting that the optimistic predictions regarding the advancements, proliferation, and adoption of AI made by many executives and Wall Street experts will prove correct, enabling CoreWeave to enjoy a veritable explosion of revenue and profits.

The risk associated with the investment, however, comes from a mix of factors, of which the fact that AI model usage remains subsidized, limiting eventual full adoption, and the many data center delays and cancellations are the most pointed.

Lastly, the buy appears to have been timed with the latest CRWV correction, considering the equity rallied 77% between March 30 and April 22, but then fell 13.88% to $105.53 on April 28.

Cathie Wood invests $14.1 million in Google stock Google, on the other hand, is a trade that came without a correction in the latest rally but appears to simultaneously be a bet that the blue-chip technology giant will offer impressive earnings after the closing bell on April 29, thus bolstering the upward momentum.

Google stock price YTD chart. Source: Finbold Looking long-term, Alphabet has been a relatively safe bet for decades due to its dominant market position, continued search engine leadership, and the foresight that enabled it to participate in multiple technology trends, including becoming one of the top companies in the ongoing AI boom.

Still, Google is somewhat exposed in the long term since it has made a significant bet that the current AI race will continue without major setbacks, while, according to numerous users, severely degrading the quality of its core search engine business over the last decade.

Featured image via Shutterstock

Intellia Therapeutics (NASDAQ:NTLA) highlighted top-line results from its Phase III HAELO trial evaluating lonvo-z, an investigational in vivo CRISPR-based gene-editing therapy for hereditary angioedema (HAE), and provided an update on regulatory progress during a company conference call.

Company outlines lonvo-z strategy and HAE unmet need Chief Executive Officer John Leonard described the update as a milestone for “the entire CRISPR field” and people living with HAE, emphasizing Intellia’s focus on in vivo gene editing delivered to the liver. Leonard said Intellia was “the first in the world to dose patients with in vivo CRISPR-based candidates and the first to advance into phase III,” and characterized the newly reported results as the “world’s first phase III data for an in vivo gene-editing candidate.”

Chief Medical Officer David Lebwohl said HAE is driven by an imbalance in the kallikrein-kinin system that leads to unpredictable swelling attacks, including potentially fatal laryngeal events. Despite widespread use of long-term prophylaxis (LTP), Lebwohl said many patients still experience breakthrough attacks and face burdens from chronic treatment, including frequent administration and payer scrutiny. He estimated there are about 7,000 treated HAE patients in the U.S., with more than 60% on LTP, and said U.S. spending is “about $4 billion annually on chronic HAE medications alone,” excluding other healthcare costs.

Lebwohl said lonvo-z is designed to permanently inactivate the KLKB1 gene to reduce kallikrein and bradykinin and “reset the system.” He also described the intended administration as outpatient: patients took a steroid at home the day before dosing, then received additional premedication and a 2- to 4-hour IV infusion before going home.

Phase III HAELO design and enrollment Marc Riedl, Professor of Medicine and Clinical Director of the US HAEA Angioedema Center at UC San Diego Health and a HAELO principal investigator, presented the Phase III results. Riedl said HAELO is a placebo-controlled, double-blind, randomized trial in Type 1 and Type 2 HAE, requiring LTP washout during screening to establish an LTP-free baseline attack rate during run-in. Patients were randomized 2:1 to a one-time 50 mg dose of lonvo-z or placebo.

Riedl said the six-month efficacy evaluation period ran from week 5 through week 28 post-dosing. After week 28, patients could enter a blinded crossover and were followed for 18 additional months before long-term follow-up.

A total of 80 patients enrolled, with 52 assigned to lonvo-z and 28 to placebo. Roughly 70% of patients in each arm were female, about half were enrolled in the U.S., and approximately 70% were using LTP at study entry, with lanadelumab most common. The mean monthly attack rate during run-in was 3.5 in both arms.

Efficacy: primary endpoint and attack-free outcomes Riedl said HAELO met the primary endpoint and all key secondary endpoints with statistical significance. For the primary endpoint (weeks 5–28), the placebo arm had a mean of 2.1 attacks per month versus 0.26 for lonvo-z, an 87% reduction.

Riedl also reported that 62% of lonvo-z patients were attack-free during the efficacy observation period versus 11% on placebo. He emphasized that these patients were also “therapy-free,” taking no other prophylactic or rescue medication during that period.

Within the lonvo-z arm, Riedl said 100% of patients achieved an attack-rate reduction from baseline. He reported 62% were attack-free and therapy-free, while the remaining 38% had not reached attack-free status over the full observation period but showed a 72% reduction versus baseline. Leonard later noted that this 38% bucket could include patients who experienced a single attack early in the observation window and none thereafter, and he said Intellia plans to present more detail at the European Academy of Allergy and Clinical Immunology (EAACI) meeting in June, including swimmer plots and additional subgroup information.

Riedl said early post-crossover data suggested continued improvement, with mean monthly attack rates “near zero” by week 36 among patients who had reached that time point, though he cautioned patient numbers beyond week 28 were limited at the cutoff.

Safety, labeling considerations, and path to filing and launch Riedl said lonvo-z had a favorable safety and tolerability profile in HAELO as of the data cutoff, with all adverse events mild or moderate and no serious adverse events in the lonvo-z arm. The most common adverse events were infusion-related reactions that were mild to moderate and transient.

Leonard also addressed a question about liver tests, saying there was a single Grade 2 ALT elevation in the trial that occurred “a couple weeks out after dosing,” resolved spontaneously within a week, and was asymptomatic with no therapy provided.

On real-world expectations, Riedl said the 62% attack-free endpoint is challenging because trials rely heavily on patient-reported outcomes, which can capture variable symptoms such as abdominal pain that may be adjudicated as an HAE attack. He added that other HAE therapies often “outperformed in the real world” versus blinded trials, including in open-label extensions, as patient confidence in treatment grows over time.

Riedl said if approved, he would discuss lonvo-z with every patient, but emphasized patient preferences vary. He added that while some patients are satisfied with current therapies, “certainly half and probably more than half” of his patients still discuss ongoing attacks, symptoms, treatment burden, and interruptions due to coverage issues. He also said most patient questions about gene editing relate to long-term safety and that broader education will be important.

Riedl pushed back on the suggestion that on-demand therapies might be unnecessary, saying guidelines still recommend all patients maintain access to on-demand treatment given the risk of rare but life-threatening airway attacks, though he expects usage could decline over time.

Leonard said Intellia recently initiated a rolling biologics license application (BLA) with the FDA and is preparing for potential approval and launch, including building commercial leadership, engaging payers and advocacy groups, and identifying target treatment centers. He said the company plans to present additional data at EAACI and aims, “if approved,” to target a commercial launch in the first half of 2027.

Chief Financial Officer Edward Dulac said Intellia is considering collaboration and distribution agreements to reach patients outside the U.S. and has not disclosed timelines for non-U.S. filings. Dulac also said payer discussions have been ongoing and “very constructive,” noting payers often evaluate one-time therapies as a multiple of the average annual cost. He said the company expects lonvo-z to be priced at a premium, though no price has been set, and added that Intellia is mindful that aggressive pricing could increase resistance, including through step edits.

About Intellia Therapeutics (NASDAQ:NTLA) Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.

Featured Articles Five stocks we like better than Intellia Therapeutics

May 05, 2026 07:30 ET  | Source: Intellia Therapeutics, Inc.

CAMBRIDGE, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that management will be participating in fireside chats at the following upcoming investor conferences:

Bank of America Securities Health Care Conference
Date: Tuesday, May 12, 2026
Fireside Chat Time: 3:40 p.m. PT
Location: Las Vegas RBC Capital Markets Global Healthcare Conference
Date: Wednesday, May 20, 2026
Fireside Chat Time: 2:35 p.m. ET
Location: New York Jefferies Global Healthcare Conference
Date: Wednesday, June 3, 2026
Fireside Chat Time: 4:55 p.m. ET
Location: New York The fireside chats will be webcast live. To join the webcasts, please visit the Events and Presentations page of the Investors & Media section on Intellia’s website at intelliatx.com. Replays of the webcasts will be available on the same page for approximately 90 days following the events.

About Intellia Therapeutics
Intellia Therapeutics, Inc. (Nasdaq: NTLA) is a leading clinical-stage biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. The company’s mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, Intellia aims to reset the standard for medicine by durably treating the root causes of disease. Learn more at intelliatx.com and follow us @intelliatx.

Investor Contact:
Jason Fredette
Vice President, Investor Relations and Corporate Communications
Intellia Therapeutics, Inc.
[email protected]

Media Contact:
Mike Tattory
Vice President
LifeSci Communications
[email protected] 

Intellia Therapeutics, Inc. (NTLA - Free Report) is expected to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended March 2026. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.

The earnings report might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower.

While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it's worth handicapping the probability of a positive EPS surprise.

Zacks Consensus EstimateThis company is expected to post quarterly loss of $0.92 per share in its upcoming report, which represents a year-over-year change of +16.4%.

Revenues are expected to be $15.53 million, down 6.6% from the year-ago quarter.

Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 5.31% higher over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.

Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.

Price, Consensus and EPS Surprise

Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core.

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.

Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.

A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.

Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).

How Have the Numbers Shaped Up for Intellia Therapeutics?For Intellia Therapeutics, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. This has resulted in an Earnings ESP of +6.14%.

On the other hand, the stock currently carries a Zacks Rank of #3.

So, this combination indicates that Intellia Therapeutics will most likely beat the consensus EPS estimate.

Does Earnings Surprise History Hold Any Clue?While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.

For the last reported quarter, it was expected that Intellia Therapeutics would post a loss of$0.99 per share when it actually produced a loss of -$0.83, delivering a surprise of +16.16%.

Over the last four quarters, the company has beaten consensus EPS estimates four times.

Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.

That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

Intellia Therapeutics appears a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.

Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.

Intellia Therapeutics, Inc. (NTLA - Free Report) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.92. This compares to a loss of $1.1 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +11.60%. A quarter ago, it was expected that this company would post a loss of $0.99 per share when it actually produced a loss of $0.83, delivering a surprise of +16.16%.

Over the last four quarters, the company has surpassed consensus EPS estimates four times.

Intellia Therapeutics, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $15.05 million for the quarter ended March 2026, missing the Zacks Consensus Estimate by 3.12%. This compares to year-ago revenues of $16.63 million. The company has topped consensus revenue estimates two times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Intellia Therapeutics shares have added about 56.7% since the beginning of the year versus the S&P 500's gain of 8.1%.

What's Next for Intellia Therapeutics?While Intellia Therapeutics has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Intellia Therapeutics was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.86 on $15.13 million in revenues for the coming quarter and -$3.50 on $68.64 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the bottom 42% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

One other stock from the same industry, Gossamer Bio (GOSS - Free Report) , is yet to report results for the quarter ended March 2026.

This biopharmaceutical company is expected to post quarterly loss of $0.18 per share in its upcoming report, which represents a year-over-year change of -12.5%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Gossamer Bio's revenues are expected to be $5.57 million, down 43.7% from the year-ago quarter.

Intellia Therapeutics, Inc. (NTLA) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Key Takeaways Intellia reported positive phase III data for lonvo-z and targets a 2027 U.S. launch. NTLA resumed nex-z phase III studies after the FDA lifted prior clinical holds in 2026. ADMA faced weaker Bivigam sales as pricing pressure and elevated IG inventories weighed on demand. ADMA Biologics (ADMA - Free Report) markets plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases.

Intellia Therapeutics (NTLA - Free Report) is a biopharmaceutical company focused on advancing CRISPR gene-editing and related technologies to develop potentially curative therapies for severe diseases. Leveraging deep expertise in science, technology, and clinical development, the company aims to transform patient care by targeting the underlying causes of disease and redefining the future of medicine.

ADMA Biologics and Intellia Therapeutics operate in distinct areas of biotechnology, but they are comparable in terms of market capitalization, as both are generally viewed as small- to mid-cap biotech companies.

Hence, let us delve into their fundamentals, growth prospects, challenges and valuation levels to make a prudent choice.  

The Case for ADMA Biologics  ADMA Biologics markets plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases.

The company’s top line currently comprises sales of three FDA-approved products — Bivigam (an Intravenous Immune Globulin [“IVIG”] product to treat primary humoral immunodeficiency), Asceniv (to treat primary immunodeficiency disease or PIDD) and Nabi-HB (to treat and provide enhanced immunity against the hepatitis B virus).

However, ADMA is currently grappling with macro challenges in the immunoglobulin (IG) products market.  

Total revenues in the first quarter were $114.5 million, down 0.3% from the year-ago quarter’s level. Bivigam revenues declined 54% year over year.  

Management noted that increased competition, elevated channel inventories and aggressive pricing activity in standard IG products created temporary pressure on top-line performance, particularly for Bivigam.

Late-quarter inventory shifts pushed certain contractual purchase orders expected in March into early April, affecting the timing of reported revenues. The company said these delays were partly due to temporary shortages in required safety stock levels at some customers and were resolved within the applicable cure period.

Asceniv, its lead product, is a plasma-derived IVIG that contains naturally occurring polyclonal antibodies. It remained the key contributor to ADMA’s revenue performance, while the company’s other product lines trended in the opposite direction. 

Asceniv recorded 28% year-over-year revenue growth, driven by record utilization, expanding prescriber adoption, strong patient adherence and continued new patient starts.

ADMA emphasized that underlying Asceniv demand remained strong, citing record utilization growth, record new patient starts, expanding prescriber breadth and steady patient adherence. ADMA also noted that April demand supported a second-quarter run rate consistent with first-quarter direct sales, giving early signs of normalization in ordering patterns.  

ADMA continued progressing SG-001, its hyperimmune globulin program targeting S. pneumoniae. Management reiterated a capital-efficient approach to development and believes the program could represent a meaningful long-term opportunity, citing an estimated $300 million to $500 million annual market opportunity if approved.

The Case for NTLA  Intellia Therapeutics represents a high-growth biotechnology company with significant upside potential driven by its leadership in CRISPR-based gene-editing therapies. The company has spent more than a decade developing proprietary technologies, including gene editing, oligonucleotides and lipid nanoparticle delivery systems, to advance first-in-class treatments for severe diseases.

Its lead candidates, lonvoguran ziclumeran (lonvo-z) for hereditary angioedema (HAE) and nexiguran ziclumeran for ATTR amyloidosis, are the first in vivo genome-editing therapies to enter phase III development. These one-time intravenous treatments target diseases with high unmet need and could potentially offer durable or curative benefits, creating a large commercial opportunity if approved.

Lonvoguran ziclumeran is an investigational one-time CRISPR-based therapy developed by NTLA to treat HAE by permanently reducing kallikrein production in the liver, with the goal of dramatically lowering or eliminating HAE attacks.

In the phase III HAELO study, lonvo-z achieved positive top-line results, reducing HAE attacks by 87% versus placebo and meeting all key secondary endpoints with strong statistical significance. The therapy also demonstrated favorable safety and tolerability, with no serious adverse events reported. Following these results, NTLA initiated a rolling BLA submission to the FDA, targeting a potential launch in the first half of 2027 in the United States.  

NTLA’s other candidate, nexiguran ziclumeran (nex-z) is an investigational one-time CRISPR-based therapy designed to silence the TTR gene in the liver, potentially halting or reversing ATTR amyloidosis through durable reduction of TTR protein levels.

The company faced a temporary setback in late 2025 after a patient death led the FDA to place clinical holds on the phase III MAGNITUDE studies on nex-z. However, the FDA lifted both holds in early 2026, allowing patient screening to resume. Nex-z is being co-developed with Regeneron Pharmaceuticals, which shares development costs and future commercial profits under the collaboration agreement.

The successful development and commercialization of these candidates could position Intellia as a pioneer in the emerging gene-editing market and significantly expand its long-term revenue potential. Intellia ended the first quarter of 2026 with $517.2 million in cash, cash equivalents, and marketable securities.

The company further strengthened its balance sheet through a public stock offering in April 2026 that generated approximately $207 million in gross proceeds. Management expects its current cash reserves to fund operations into 2028, extending well beyond the anticipated U.S. commercial launch of lonvo-z in the first half of 2027.  

A Look at Estimates: ADMA vs NTLA  The Zacks Consensus Estimate for ADMA’s 2026 sales implies a year-over-year increase of 5.86%, and that for earnings per share (EPS) suggests an improvement of 40%.  However, EPS estimates for 2026 and 2027 have moved south in the past 60 days.  

ADMA’s Estimate Movement  
Image Source: Zacks Investment Research

The Zacks Consensus Estimate for NTLA’s 2026 sales implies a year-over-year decrease of 7.75%, while that for EPS suggests an improvement of 13.65%. Loss estimates for both 2026 and 2027 have narrowed in the past 60 days.  

NTLA Estimate Movement
Image Source: Zacks Investment Research

Price Performance and Valuation of ADMA and NTLAFrom a price-performance perspective, NTLA has performed well so far this year versus ADMA. Shares of ADMA have plunged 55.3%. In contrast, NTLA shares have surged 40.3%. The industry has declined 0.5% in the said period.  

Image Source: Zacks Investment Research

From a valuation standpoint, ADMA’s shares currently trade at 3.19X forward sales, lower than 9.71X for NTLA.  

Image Source: Zacks Investment Research

Which Stock Is a Better Pick for Now?  ADMA currently has a Zacks Rank #5 (Strong Sell) while NTLA carries a Zacks Rank #3 (Hold).  

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Although demand for ADMA’s Asceniv continues to be solid, broader pressure across the U.S. plasma-derived products space suggests a more cautious near-term outlook. Competitive intensity, pricing dynamics and market share concerns could continue to weigh on growth visibility and margin expansion prospects.  

In contrast, Intellia is a clinical-stage biotechnology company developing CRISPR-based gene-editing therapies designed to potentially cure severe diseases by targeting their underlying genetic causes. NTLA strengthened its investment case after reporting positive phase III top-line data for lonvo-z in April 2026, with a commercial launch planned for the first half of 2027. Successful commercialization could position Intellia as a pioneer in the emerging gene-editing market and significantly expand its long-term revenue potential.

Hence, we prefer NTLA over ADMA, given its significant growth opportunity in genetic medicine and the recent positive revisions to earnings estimates.

June 01, 2026 07:30 ET  | Source: Intellia Therapeutics, Inc.

CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that data from the global Phase 3 HAELO clinical trial of lonvo-z (formerly known as NTLA-2002) in hereditary angioedema (HAE) will be presented in a late-breaking oral presentation at the European Academy of Allergy & Clinical Immunology (EAACI) Annual Congress 2026, taking place June 12-15 in Istanbul, Türkiye. Intellia will also have a poster presentation detailing the burdens experienced by HAE patients living outside the United States.

Late-Breaking Oral Presentation Details:

Title: HAELO, a Phase 3, Global, Randomised, Double-Blind, Placebo-Controlled Study of Lonvoguran Ziclumeran, a CRISPR-Based Gene Editing Therapy, in Patients with Hereditary Angioedema
Session: Immune deficiencies and autoimmunity
Data and Time: Saturday, June 13, 2026, from 8:45 – 9:45 a.m. TRT
Presentation Number: 100217
Presenter: Danny Cohn, M.D., Ph.D., Internist, Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Center, University of Amsterdam Poster Presentation Details:

Title: Barriers to Normalization with Existing Treatments Among People Living with Hereditary Angioedema in Europe
Session: Immune deficiencies and autoimmunity 02
Data and Time: Friday, June 12, 2026, from 12:00 – 1:00 p.m. TRT
Poster Number: D1.336
Presenter: Henriette Farkas, M.D., Ph.D., Professor of Allergy and Clinical Immunology Director of the Hungarian Angioedema Center of Reference and Excellence, Department of Internal Medicine and Hematology, Semmelweis University About Lonvo-z
Based on Nobel Prize-winning CRISPR/Cas9 technology, lonvo-z has the potential to become the first one-time treatment for hereditary angioedema (HAE). Lonvo-z is an in vivo CRISPR gene editing candidate that is intended to permanently lower kallikrein by inactivating the kallikrein B1 (KLKB1) gene with a single dose. Lonvo-z has received five notable regulatory designations: Orphan Drug and RMAT Designation by the U.S. Food and Drug Administration (FDA), the Innovation Passport by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA), Priority Medicines (PRIME) Designation by the European Medicines Agency, as well as Orphan Drug Designation (ODD) by the European Commission.

About Hereditary Angioedema
Hereditary angioedema (HAE) is a rare, genetic disease characterized by severe, recurring and unpredictable inflammatory attacks in various organs and tissues of the body, which can be painful, debilitating and life-threatening. It is estimated that one in 50,000 people are affected by HAE. There are preventative and on-demand treatment options to help manage the condition, including long- and short-term prophylaxis used to prevent swelling attacks. Current treatment options often include lifelong therapies, which may require chronic intravenous (IV) or subcutaneous (SC) administration as often as twice per week or daily oral administration to ensure constant pathway suppression for disease control. Despite chronic administration, breakthrough attacks still occur. Kallikrein inhibition is a clinically validated strategy for the preventive treatment of HAE attacks.

About Intellia Therapeutics
Intellia Therapeutics, Inc. (Nasdaq: NTLA) is a leading clinical-stage biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. The company’s mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, Intellia aims to reset the standard for medicine by durably treating the root causes of disease. Learn more at intelliatx.com and follow us @intelliatx.

Investor Contact:
Jason Fredette
Vice President, Investor Relations and Corporate Communications
Intellia Therapeutics, Inc.
[email protected]

Media Contact:
Mike Tattory
Vice President
LifeSci Communications
[email protected] 

A month has gone by since the last earnings report for Intellia Therapeutics, Inc. (NTLA - Free Report) . Shares have lost about 7.9% in that time frame, underperforming the S&P 500.

Will the recent negative trend continue leading up to its next earnings release, or is Intellia Therapeutics due for a breakout? Well, first let's take a quick look at its most recent earnings report in order to get a better handle on the recent drivers for Intellia Therapeutics, Inc. before we dive into how investors and analysts have reacted as of late.

Intellia Q1 Earnings Beat Estimates, Revenues Miss MarkIntellia incurred a first-quarter 2026 loss of 81 cents per share, narrower than the Zacks Consensus Estimate of a loss of 92 cents. In the year-ago quarter, the company had incurred a loss of $1.10 per share.

Intellia’s total revenues currently comprise only collaboration revenues. The company reported revenues of $15 million for the first quarter of 2026, which missed the Zacks Consensus Estimate of $16 million. Total revenues declined 9.5% year over year.

Quarter in DetailResearch and development expenses totaled $80.7 million, down 25.5% from the year-ago quarter’s figure. The decrease was due to lower employee-related expenses, stock-based compensation and reduced spending on research materials and contracted services.

General and administrative expenses in the first quarter were $34.8 million, up 20.1% year over year, primarily due to continued investments in building the company’s commercial infrastructure and higher legal expenses, partially offset by lower stock-based compensation.

As of March 31, 2026, Intellia had cash, cash equivalents and marketable securities worth $517.2 million compared with $605.1 million as of Dec. 31, 2025.

Following an underwritten public offering of common stock, the company expects its cash runway to support operations into 2028.

How Have Estimates Been Moving Since Then?In the past month, investors have witnessed a upward trend in estimates revision.

The consensus estimate has shifted 7.62% due to these changes.

VGM ScoresAt this time, Intellia Therapeutics has a average Growth Score of C, however its Momentum Score is doing a lot better with an A. However, the stock has a grade of F on the value side, putting it in the fifth quintile for value investors.

Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.

OutlookEstimates have been broadly trending upward for the stock, and the magnitude of these revisions looks promising. Notably, Intellia Therapeutics has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.

Performance of an Industry PlayerIntellia Therapeutics belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Incyte (INCY - Free Report) , has gained 4.1% over the past month. More than a month has passed since the company reported results for the quarter ended March 2026.

Incyte reported revenues of $1.27 billion in the last reported quarter, representing a year-over-year change of +20.9%. EPS of $1.81 for the same period compares with $1.16 a year ago.

Incyte is expected to post earnings of $1.80 per share for the current quarter, representing a year-over-year change of +14.7%. Over the last 30 days, the Zacks Consensus Estimate has changed -3.3%.

Incyte has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of B.

Arlo remains a compelling buy as small caps lag and market volatility persists, with fundamentals supporting upside. ARLO's ARR and paid subscriber base are growing over 20% y/y, driving EBITDA and free cash flow expansion. The company's improving margin profile and disciplined inventory management underpin its long-term growth thesis.

Posted by Defense World Staff on Apr 8th, 2026

Riskified (NYSE:RSKD – Get Free Report) and Arlo Technologies (NYSE:ARLO – Get Free Report) are both small-cap computer and technology companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends.

Profitability This table compares Riskified and Arlo Technologies’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets Riskified -8.00% -5.63% -4.24% Arlo Technologies 2.82% 10.76% 4.03% Analyst Ratings This is a summary of current recommendations for Riskified and Arlo Technologies, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Riskified 1 3 3 0 2.29 Arlo Technologies 0 2 3 0 2.60 Riskified currently has a consensus target price of $5.96, indicating a potential upside of 45.79%. Arlo Technologies has a consensus target price of $23.33, indicating a potential upside of 64.96%. Given Arlo Technologies’ stronger consensus rating and higher possible upside, analysts plainly believe Arlo Technologies is more favorable than Riskified.

Institutional & Insider Ownership 59.0% of Riskified shares are owned by institutional investors. Comparatively, 83.2% of Arlo Technologies shares are owned by institutional investors. 17.4% of Riskified shares are owned by company insiders. Comparatively, 5.2% of Arlo Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation This table compares Riskified and Arlo Technologies”s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Riskified $344.64 million 1.76 -$27.57 million ($0.17) -24.04 Arlo Technologies $529.30 million 2.86 $14.93 million $0.13 108.81 Arlo Technologies has higher revenue and earnings than Riskified. Riskified is trading at a lower price-to-earnings ratio than Arlo Technologies, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk Riskified has a beta of 1.33, indicating that its stock price is 33% more volatile than the S&P 500. Comparatively, Arlo Technologies has a beta of 1.71, indicating that its stock price is 71% more volatile than the S&P 500.

Summary Arlo Technologies beats Riskified on 12 of the 13 factors compared between the two stocks.

About Riskified (Get Free Report)

Riskified Ltd., together with its subsidiaries, develops and offers an e-commerce risk management platform that allows online merchants to create trusted relationships with consumers in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and the Americas. It offers Chargeback Guarantee that ensures the legitimacy of merchants' online orders; Policy Protect, a machine learning solution designed to detect and prevent refund and returns policy abuse in real-time; Account Secure, a solution that cross-checks every login attempt; Dispute Resolve, which is used to compile submissions for fraud and non-fraud related chargeback issues; and PSD2 Optimize that helps merchants avoid bank authorization failures and abandoned shopping carts. The company serves direct-to-consumer brands, online-only retailers, omnichannel retailers, online marketplaces, and e-commerce service providers in various industries, such as payments, money transfer and crypto, tickets and travel, electronics, home, and fashion and luxury goods. Riskified Ltd. was incorporated in 2012 and is headquartered in Tel Aviv, Israel.

About Arlo Technologies (Get Free Report)

Arlo Technologies, Inc., together with its subsidiaries, provides a cloud-based platform in the Americas, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers Arlo Essential Cameras and Doorbells (2nd Generation) delivers smart home protection, including automated privacy shield, 180-degree field of view, and 2K video resolution; Arlo Home Security System, an all-in-one multi-sensor that provides access to security experts for monitoring and responding to emergency situations; Arlo Pro 5S, a wireless 2K video resolution security camera; Arlo Go 2, a camera for monitoring remote areas, large properties, construction sites, vacation homes, boat or RV slips, and hard-to-access areas; Arlo Ultra 2 provides 4K video with HDR, an ultra-wide, 180-degree field of view, auto zoom and tracking on moving objects, and color night vision; and Arlo Floodlight Camera, a wire-free floodlight camera. It provides security system accessories, charging accessories, and mounts. In addition, the company offers Arlo Secure subscriptions, including emergency response secure plus plan; 2K secure plan and 4K secure plus plan cloud-based video recording; unlimited cameras; advanced object detection; smart interactive notifications; smoke and CO alarm detection; cloud-based activity zone; call a friend; and 24/7 priority support and professional monitoring services; Arlo Total Security, a subscription which provides 24/7 professional monitoring and security hardware; Arlo Safe, a personal safety app that offers one-touch emergency response, family safety, and crash detection and response services; and Arlo SmartCloud, a SaaS solution that delivers security cloud services for business. It sells its products through retailers, wholesale distributors, broadcast channels, wireless carriers, and security solution providers, as well as through its website. Arlo Technologies, Inc. was incorporated in 2018 and is headquartered in Carlsbad, California.

Receive News & Ratings for Riskified Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Riskified and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEAnalyzing Active Power (OTCMKTS:PIOE) & Millrose Properties (NYSE:MRP)

NEXT HEADLINE »Ralliant (NYSE:RAL) versus Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) Head-To-Head Analysis

On April 13, 2026, Arlo Technologies Inc ARLO shares rose 4.6% to a current price of $13.72. Over the past 52 weeks, the stock has traded between $8.50 and $19.94, showcasing significant volatility. The recent price increase comes amidst a backdrop of fluctuations, as the stock has experienced a -1.1% decline over the past week and is down 1.9% year-to-date, yet boasts a remarkable 54.5% gain over the past year.

GF Value™ verdict: Current price of $13.72 vs GF Value of $10.40 indicates the stock is 31.9% overvalued.GF Score™ of 67/100 signifies an above-average ranking in terms of overall quality and performance.Notable signal: Insider activity shows that insiders sold $9.4M worth of shares in the last three months, indicating potential caution among company leaders. Is ARLO Overvalued or Undervalued? Analyzing the discrepancy between the current price of $13.72 and the GF Value™ of $10.40 reveals that Arlo Technologies Inc is currently overvalued by approximately 31.9%. The GF Valuation label classifies the stock as significantly overvalued, suggesting caution for potential investors. A significant risk is present, as buying shares at this inflated price could expose investors to a downturn if the market corrects to reflect its intrinsic value. GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates.

The margin of safety appears limited as the stock trades well above its calculated fair value, indicating that current investors may be paying a premium that does not align with the company's fundamentals. This valuation discrepancy may lead to a re-evaluation of the stock price if future performance does not meet market expectations.

How Does ARLO's Valuation Compare to Its History? Metric Current Historical P/E (TTM) 105.5x 115.5x (5-Year Median) Forward P/E 17.0x N/A The current P/E (TTM) of 105.5x is 9% below its 5-year median of 115.5x, indicating that the stock is trading slightly below its historical valuation multiples. However, this analysis generally aligns with the GF Value™ verdict of being overvalued, as such high P/E ratios may not be sustainable in the long run, particularly in light of the significant gap between the current price and GF Value™.

What Does ARLO's GF Score™ Tell Us? Metric Rating GF Score™ 67/100 Financial Strength 7/10 Profitability 3/10 Growth 2/10 Valuation 5/10 Momentum 8/10 The GF Score™ of 67/100 highlights that Arlo Technologies Inc holds some strong attributes, particularly in Financial Strength with a rating of 7/10 and Momentum with a rating of 8/10. However, the weaker areas, such as Profitability (3/10) and Growth (2/10), suggest that while the company may be stable, it may struggle with generating consistent profits and expanding effectively. This mixed score indicates a need for cautious evaluation before making any investment decisions.

What Are Insiders Doing with ARLO Stock? Recent insider activity shows that insiders have sold approximately $9.4 million worth of shares over the last three months, with no reported purchases. This trend can often signal a lack of confidence in the company's short-term prospects or a desire to capitalize on current stock prices. Such selling activity may raise concerns for potential investors regarding the company's future performance and strategic direction.

What This Means for Investors Based on the GF Value™ assessment, Arlo Technologies Inc ARLO is currently overvalued at a price of $13.72 in comparison to the GF Value™ of $10.40. This overvaluation suggests potential risks for investors, particularly in light of the company's recent insider selling and mixed financial metrics. Caution is advised when considering an investment in this stock.

For the complete analysis, visit the Arlo Technologies Inc ARLO stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.

Frequently Asked Questions What is ARLO's GF Score™?

ARLO's GF Score™ is 67/100, indicating an above-average ranking in overall quality and performance, suggesting that while there are strengths, there are also significant areas for improvement.

Is ARLO overvalued or undervalued?

ARLO is currently overvalued with a GF Value™ of $10.40 compared to its current price of $13.72, indicating a potential risk for investors.

What is ARLO's P/E ratio?

ARLO's P/E ratio (TTM) is 105.5x, which is slightly below its 5-year median of 115.5x, suggesting a valuation that, while high, is marginally more favorable than historical averages.

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].

-

SAN JOSE, Calif.--(BUSINESS WIRE)--Arlo Technologies, Inc. (NYSE: ARLO), a leading provider of smart security services, today announced that it will hold a conference call with investors and analysts on Thursday, May 7, 2026 at 5:00 p.m. ET (2:00 p.m. PT) to discuss the Company’s first quarter 2026 results. The news release announcing the first quarter 2026 results will be disseminated on May 7, 2026 after the market closes.

The toll-free dial-in number for the live audio call beginning at 5:00 p.m. ET (2:00 p.m. PT) on May 7, 2026 is (800) 715-9871. The international dial-in number for the live audio call is (646) 307-1963. The conference ID for the call is 5685809. A live webcast of the conference call will be available on Arlo’s Investor Relations website at http://investor.arlo.com. A replay of the call will be available via the web at http://investor.arlo.com.

About Arlo Technologies, Inc.

Arlo is an award-winning, industry leader that is transforming the ways in which people can protect everything that matters to them with advanced home, business, and personal security solutions. Arlo's deep expertise in AI- and CV-powered analytics, cloud services, user experience and product design, and innovative wireless and RF connectivity enables the delivery of a seamless, smart security experience for Arlo users that is easy to set up and interact with every day. Arlo's cloud-based platform provides users with visibility, insight and a powerful means to help protect and connect in real-time with the people and things that matter most, from any location with a Wi-Fi or a cellular connection. Arlo has recently launched several categories of award-winning connected devices, software and services. These include wire-free, smart Wi-Fi and LTE-enabled security cameras, video doorbells, floodlights, security system, and Arlo's subscription service, Arlo Secure.

With a mission to bring users peace of mind, Arlo is as passionate about protecting user privacy as it is about safeguarding homes and families. Arlo is committed to implementing industry standards for data protection designed to keep users' personal information private and in their control. Arlo provides enhanced controls for user data, supports privacy legislation, keeps user data safely secure, and puts security at the forefront of company culture.

© 2026 Arlo Technologies, Inc., Arlo and the Arlo logo are trademarks and/or registered trademarks of Arlo Technologies, Inc. and/or certain of its affiliates in the United States and/or other countries. Other brand and product names are for identification purposes only and may be trademarks or registered trademarks of their respective holder(s). The information contained herein is subject to change without notice. Arlo shall not be liable for technical or editorial errors or omissions contained herein. All rights reserved.

Source: Arlo-F

More News From Arlo Technologies, Inc.

Back to Newsroom

Record subscriptions and services revenue of $90 million, growing 31% year over year

Annual recurring revenue (ARR)(1) of $357 million, growing 29% year over year

Record GAAP gross margin of 48%, growing 400 basis points and record non-GAAP gross margin(2) of 50%, growing 460 basis points

Record GAAP net income of $15 million and record adjusted EBITDA(2) of $30 million; adjusted EBITDA margin of 20%

Record GAAP EPS of $0.14 and record non-GAAP EPS of $0.28

CARLSBAD, Calif.--(BUSINESS WIRE)--Arlo Technologies, Inc. (NYSE: ARLO), a leading smart home security platform company, today reported financial results for the first quarter ended March 29, 2026.

“Our strong momentum continued into 2026 as Arlo delivered outstanding financial results in the first quarter, generating exceptional revenue growth and profitability. Record subscriptions and services revenue of $90 million and ARR of $357 million both grew by about 30%. Accelerating profitability resulted in adjusted EBITDA of $30 million and non-GAAP earnings per share of $0.28 which both grew by over 85% year over year,” said Matthew McRae, Chief Executive Officer of Arlo Technologies. “Sustained operational excellence in our core business enabled us to confidently leverage our capital allocation program to expand into new market opportunities as evidenced by our acquisition of Aloe Care in April. We believe these types of inorganic opportunities combined with the scale of our strategic partnerships will provide additional durable growth vectors on our path to surpass our long-range targets early.”

Financial Summary

Record subscriptions and services revenue of $90.1 million, an increase of 30.9% year over year, accounting for 59.9% of total revenues. Ended with ARR of $356.9 million, growing 29.2% year over year. GAAP subscriptions and services gross margin of 83.7% and record non-GAAP subscriptions and services gross margin of 85.4%; up 150 and 230 basis points year over year, respectively. Record GAAP gross margin of 48.3% and record non-GAAP gross margin of 50.1%; up 400 and 460 basis points year over year, respectively. Record adjusted EBITDA of $30.4 million, up 85.3% year over year with adjusted EBITDA margin of 20.2%. Record GAAP EPS of $0.14 and record non-GAAP EPS of $0.28. Cumulative paid accounts increased to 6.0 million, growing 22.6% year over year. Free cash flow (FCF)(3) of $25.4 million with FCF margin of 16.9%. Cash and cash equivalents and short-term investments of $167.5 million, up $14.4 million year over year. Business Highlights

Acquisition of Aloe Care Health to accelerate the expansion of our AI-powered services for aging-in-place care in collaboration with health providers, patients, and their families. Surpassed 6 million paid accounts, a significant milestone in our long-range plan to reach 10 million paid accounts. Repurchased $8.0 million of common stock during the first quarter, as part of a recent newly authorized stock repurchase program of $50 million of our shares. Recorded a gain from the sale of our strategic investment in Origin Wireless of $6.4 million resulting in a 51% return. Three Months Ended

March 29,
2026

December 31,
2025

March 30,
2025

(In thousands, except percentage and per share data)

Revenue

$ 

150,382

$

141,297

$

119,066

GAAP gross margin

48.3

%

46.4

%

44.3

%

Non-GAAP gross margin (2)

50.1

%

47.8

%

45.5

%

GAAP earnings (loss) per share - basic

$ 

0.14

$

0.05

$

(0.01

)

Non-GAAP EPS - diluted (2)

$ 

0.28

$

0.22

$

0.15

The second quarter 2026 Outlook (4) (5)

A reconciliation of our outlook on a GAAP and non-GAAP basis is provided for the three months ended June 28, 2026 in the following table:

Revenue

EPS - diluted

(In millions, except per share data)

GAAP

$145 - $155

$0.00 - $0.06

Adjustments for stock-based compensation expense and others

—

$0.17

Non-GAAP

$145 - $155

$0.17 - $0.23

Investor Conference Call / Webcast Details

Arlo will review the first quarter 2026 results and discuss management’s expectations for the second quarter 2026 today, Thursday, May 7, 2026 at 5:00 p.m. ET (2:00 p.m. PT). To view the accompanying presentation, a live webcast of the conference call will be available on Arlo’s Investor Relations website at https://investor.arlo.com. The toll-free dial-in number for the live audio call is (800) 715-9871. The international dial-in number for the live audio call is (646) 307-1963. The conference ID for the call is 5685809. A replay of the call will be available via the web at https://investor.arlo.com.

About Arlo Technologies, Inc.

Arlo is an award-winning, industry leader that is transforming the ways in which people can protect everything that matters to them with advanced home, business, and personal security solutions. Arlo's deep expertise in AI- and CV-powered analytics, cloud services, user experience and product design, and innovative wireless and RF connectivity enables the delivery of a seamless, smart security experience for Arlo users that is easy to set up and interact with every day. Arlo's cloud-based platform provides users with visibility, insight and a powerful means to help protect and connect in real-time with the people and things that matter most, from any location with a Wi-Fi or a cellular connection. Arlo has recently launched several categories of award-winning connected devices, software and services. These include wire-free, smart Wi-Fi and LTE-enabled security cameras, video doorbells, floodlights, security system, and Arlo's subscription service, Arlo Secure.

With a mission to bring users peace of mind, Arlo is as passionate about protecting user privacy as it is about safeguarding homes and families. Arlo is committed to implementing industry standards for data protection designed to keep users' personal information private and in their control. Arlo provides enhanced controls for user data, supports privacy legislation, keeps user data safely secure, and puts security at the forefront of company culture.

© 2026 Arlo Technologies, Inc., Arlo and the Arlo logo are trademarks and/or registered trademarks of Arlo Technologies, Inc. and/or certain of its affiliates in the United States and/or other countries. Other brand and product names are for identification purposes only and may be trademarks or registered trademarks of their respective holder(s). The information contained herein is subject to change without notice. Arlo shall not be liable for technical or editorial errors or omissions contained herein. All rights reserved.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 for Arlo Technologies, Inc.:

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. The words “anticipate,” “expect,” “believe,” “will,” “may,” “should,” “estimate,” “project,” “outlook,” “forecast” or other similar words are used to identify such forward-looking statements. However, the absence of these words does not mean that the statements are not forward-looking. The forward-looking statements represent our expectations or beliefs concerning future events based on information available at the time such statements were made and include statements regarding our potential future business, operating performance and financial condition, including descriptions of our expected revenue and profitability, GAAP and non-GAAP gross margins, adjusted EBITDA and adjusted EBITDA margins, tax rates, expenses, cash outlook, free cash flow and free cash flow margins; strategic objectives and initiatives; expectations regarding the accelerated expansion of our AI-powered services for aging-in-place care and the expansion of our presence in the AI-driven smart home security market; expectations regarding the anticipated benefits, synergies and value creation from our recent acquisitions, including the acquisitions of Aloe Care and Canary, and the successful integration thereof; expectations regarding the realization of returns on our strategic investments, including the disposition of our investment in Origin Wireless; expectations regarding our ability to combine our strategic opportunities with the scale of our strategic partnerships to provide additional growth vectors on our quest to surpass our long-range targets early; and others. These statements are based on management's current expectations and are subject to certain risks and uncertainties, including the following: future demand for our products may be lower than anticipated, including due to inflation, fluctuating consumer confidence, banking failures and high interest rates; we may be unsuccessful in developing and expanding our sales and marketing capabilities; we may not be able to increase sales of our paid subscription services; consumers may choose not to adopt our new product offerings or adopt competing products; product performance may be adversely affected by real world operating conditions; we may be unsuccessful or experience delays in manufacturing and distributing our new and existing products; we may fail to manage costs and cost saving initiatives, the cost of developing new products and manufacturing and distribution of our existing offerings; we may fail to successfully integrate acquired businesses, technologies or personnel, or to realize the anticipated benefits, synergies or cost savings from our recent acquisitions; we may experience difficulties retaining key employees of acquired companies; the costs and management attention associated with the integration of acquired businesses may be greater than anticipated; and we may not realize the expected returns on our future strategic investments, if any. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in such forward-looking statements.

Under the current U.S. administration, tariffs, and retaliatory tariffs imposed by other nations, have created a dynamic and unpredictable trade landscape, which is adversely impacting, and may continue to adversely impact, our business. Current or future tariffs impacting our products, which are manufactured outside of the United States, have raised and may further raise our product costs. In addition, other trade restrictions could negatively impact our ability to obtain finished products from our ex-U.S. manufacturers and suppliers and, therefore, delay or impede our product deliveries. Tariff-related cost pressures and supply chain disruptions may lead to reputational harm if we are unable to deliver products or services on expected timelines or if any price increases are poorly received by customers or business partners. Furthermore, ongoing uncertainty regarding trade disputes and other political tensions between the United States and other countries, including in Asia, may also exacerbate unfavorable macroeconomic conditions, which may negatively impact international customer demand for our products or services and may lead to increased preference for local competitors. While we continue to monitor these developments, the full impact of these risks remains uncertain, and any prolonged economic downturn, escalation in trade tensions or deterioration in international perception of U.S.-based companies could materially and adversely affect our business, results of operations and financial condition.

Further information on potential risk factors that could affect our business are detailed in our periodic filings with the Securities and Exchange Commission, including, but not limited to, those risks and uncertainties listed in the section entitled “Risk Factors” in the most recently filed Annual Report and Quarterly Report filed with the Securities and Exchange Commission (the “SEC”) and subsequent filings with the SEC. Given these circumstances, you should not place undue reliance on these forward-looking statements. We undertake no obligation to release publicly any revisions to any forward-looking statements contained herein to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Non-GAAP Financial Measures:

To supplement our unaudited financial data prepared on a basis consistent with U.S. Generally Accepted Accounting Principles (“GAAP”), we disclose certain non-GAAP financial measures that exclude certain charges, including non-GAAP gross profit, non-GAAP gross margin, adjusted EBITDA, adjusted EBITDA margin, non-GAAP net income and non-GAAP earnings per diluted share. These supplemental measures exclude adjustments for stock-based compensation expense, acquisition-related expense, gain on sale of long-term investment, amortization of software development cost, depreciation expenses, and the related tax effects. In addition, we use free cash flow as a non-GAAP measure when assessing the sources of liquidity, capital resources, and quality of earnings. We believe that free cash flow is helpful in understanding our capital requirements and provides an additional means to reflect the cash flow trends in our business.

These non-GAAP measures are not in accordance with, or an alternative for GAAP, and may be different from similarly-titled non-GAAP measures used by other companies. We believe that these non-GAAP measures have limitations in that they do not reflect all of the amounts associated with our results of operations as determined in accordance with GAAP and that these measures should only be used to evaluate our results of operations in conjunction with the corresponding GAAP measures. The presentation of this additional information is not meant to be considered in isolation or as a substitute for the most directly comparable GAAP measures. We compensate for the limitations of non-GAAP financial measures by relying upon GAAP results to gain a complete picture of our performance.

In calculating non-GAAP financial measures, we exclude certain items to facilitate a review of the comparability of our operating performance on a period-to-period basis because such items are not, in our view, related to our ongoing operational performance. We use non-GAAP measures to evaluate the operating performance of our business, for comparison with forecasts and strategic plans, and for benchmarking performance externally against competitors. In addition, management’s incentive compensation is determined using certain non-GAAP measures. Since we find these measures to be useful, we believe that investors benefit from seeing results “through the eyes” of management in addition to seeing GAAP results. We believe that these non-GAAP measures, when read in conjunction with our GAAP measures, provide useful information to investors by offering:

the ability to make more meaningful period-to-period comparisons of our on-going operating results; the ability to better identify trends in our underlying business and perform related trend analyses; a better understanding of how management plans and measures our underlying business; and an easier way to compare our operating results against analyst financial models and operating results of competitors that supplement their GAAP results with non-GAAP financial measures. The following are explanations of the adjustments that we incorporate into non-GAAP measures, as well as the reasons for excluding them in the reconciliations of these non-GAAP financial measures:

Stock-based compensation expense consists of non-cash charges for the estimated fair value of restricted stock units, performance-based restricted stock units, and shares under the employee stock purchase plan granted to employees, and the payroll taxes associated with stock-based compensation. We believe that the exclusion of these charges provides for more accurate comparisons of our operating results to peer companies due to the varying available valuation methodologies, subjective assumptions and the variety of award types. In addition, we believe it is useful to investors to understand the specific impact stock-based compensation expense has on our operating results.

Other non-GAAP items are the result of either unique or unplanned events, including, when applicable: acquisition-related expense, gain on sale of long-term investment, amortization of software development cost, depreciation expenses, and the related tax effects. It is difficult to predict the occurrence or estimate the amount or timing of these items in advance. Although these events are reflected in our GAAP financial statements, these unique transactions may limit the comparability of our on-going operations with prior and future periods. The amounts result from events that often arise from unforeseen circumstances, which often occur outside of the ordinary course of continuing operations. Therefore, the amounts do not accurately reflect the underlying performance of our continuing business operations for the period in which they are incurred.

Source: Arlo-F

  ARLO TECHNOLOGIES, INC.

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except share and per share data)

  As of

March 29, 2026

December 31, 2025

ASSETS

Current assets:

Cash and cash equivalents

$

152,636

$

146,440

Short-term investments

14,862

19,985

Accounts receivable, net

52,174

39,666

Inventories

43,958

41,185

Prepaid expenses and other current assets

12,045

13,210

Total current assets

275,675

260,486

Property and equipment, net

14,178

13,158

Operating lease right-of-use assets, net

8,691

9,195

Goodwill

38,544

11,038

Intangible assets, net

19,490

—

Long-term investment

—

12,500

Other non-current assets

3,614

4,171

Total assets

$

360,192

$

310,548

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:

Accounts payable

$

40,184

$

42,826

Deferred revenue

52,187

37,139

Accrued liabilities

89,331

92,372

Total current liabilities

181,702

172,337

Non-current operating lease liabilities

6,230

6,743

Other non-current liabilities

12,858

3,627

Total liabilities

200,790

182,707

Commitments and contingencies

Stockholders’ Equity:

Preferred stock: $0.001 par value; 50,000,000 shares authorized; none issued or outstanding

—

—

Common stock: $0.001 par value; 500,000,000 shares authorized; shares issued and outstanding: 108,745,373 at March 29, 2026 and 105,030,947 at December 31, 2025

108

105

Additional paid-in capital

527,457

510,759

Accumulated other comprehensive income (loss)

(1

)

16

Accumulated deficit

(368,162

)

(383,039

)

Total stockholders’ equity

159,402

127,841

Total liabilities and stockholders’ equity

$

360,192

$

310,548

  ARLO TECHNOLOGIES, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except percentage and per share data)

  Three Months Ended

March 29,
2026

December 31,
2025

March 30,
2025

Revenue:

Subscriptions and services

$

90,099

$

89,390

$

68,849

Products

60,283

51,907

50,217

Total revenue

150,382

141,297

119,066

Cost of revenue:

Subscriptions and services

14,682

15,412

12,265

Products

63,032

60,352

54,074

Total cost of revenue

77,714

75,764

66,339

Gross profit

72,668

65,533

52,727

Gross margin

48.3

%

46.4

%

44.3

%

Operating expenses:

Research and development

22,814

20,852

16,165

Sales and marketing

22,654

23,077

20,203

General and administrative

18,207

16,887

17,785

Other operating expense

1,435

—

25

Total operating expenses

65,110

60,816

54,178

Income (loss) from operations

7,558

4,717

(1,451

)

Operating margin

5.0

%

3.3

%

(1.2

)%

Other income, net:

Gain on sale of long-term investment

6,423

—

—

Interest income, net

1,241

1,284

1,316

Other income (expense), net

70

102

(198

)

Total other income, net

7,734

1,386

1,118

Income (loss) before income taxes

15,292

6,103

(333

)

Provision for income taxes

415

339

502

Net income (loss)

$

14,877

$

5,764

$

(835

)

Earnings (loss) per share:

Basic

$

0.14

$

0.05

$

(0.01

)

Diluted

$

0.13

$

0.05

$

(0.01

)

Weighted-average common shares outstanding:

Basic

106,995

105,434

102,217

Diluted

110,488

110,353

102,217

  ARLO TECHNOLOGIES, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

  Three Months Ended

March 29, 2026

March 30, 2025

Cash flows from operating activities:

Net income (loss)

$

14,877

$

(835

)

Adjustments to reconcile net income (loss) to net cash provided by operating activities:

Stock-based compensation expense, net of amounts capitalized

19,734

17,012

Depreciation and amortization

1,697

829

Gain on sale of long-term investment

(6,423

)

—

Allowance for credit losses and non-cash changes to reserves

949

416

Deferred income taxes

241

(155

)

Discount accretion on investments and other

(57

)

(657

)

Changes in assets and liabilities, net of assets acquired:

Accounts receivable, net

(12,490

)

11,287

Inventories

(1,828

)

5,648

Prepaid expenses and other assets

1,481

354

Accounts payable

(3,622

)

(14,983

)

Deferred revenue

14,811

15,597

Accrued and other liabilities

(1,507

)

(3,594

)

Net cash provided by operating activities

27,863

30,919

Cash flows from investing activities:

Purchases of property and equipment, including capitalized software

(2,419

)

(2,803

)

Purchases of short-term investments

(14,825

)

(44,049

)

Purchase of long-term investment

—

(12,500

)

Acquisition of business

(36,000

)

—

Proceeds from maturities of short-term investments

19,988

45,000

Proceeds from sale of long-term investment

18,923

—

Net cash used in investing activities

(14,333

)

(14,352

)

Cash flows from financing activities:

Proceeds from employee stock plans

—

649

Repurchases of common stock

(7,334

)

(15,239

)

Net cash used in financing activities

(7,334

)

(14,590

)

Net increase in cash and cash equivalents

6,196

1,977

Cash and cash equivalents at beginning of period

146,440

82,032

Cash and cash equivalents at end of period

$

152,636

$

84,009

Non-cash investing and financing activities:

Purchases of property and equipment included in accounts payable and accrued liabilities

$

463

$

1,164

Stock-based compensation expense capitalized for software development

$

305

$

601

Stock repurchases included in accounts payable

$

1,021

$

—

ARLO TECHNOLOGIES, INC.

RECONCILIATIONS OF GAAP MEASURES TO NON-GAAP MEASURES (UNAUDITED)

(In thousands, except percentage data)

  Three Months Ended

March 29,
2026

December 31,
2025

March 30,
2025

GAAP gross profit:

Subscriptions and services

$

75,417

$

73,978

$

56,584

Products

(2,749

)

(8,445

)

(3,857

)

Total GAAP gross profit

72,668

65,533

52,727

GAAP gross margin:

Subscriptions and services

83.7

%

82.8

%

82.2

%

Products

(4.6

)%

(16.3

)%

(7.7

)%

Total GAAP gross margin

48.3

%

46.4

%

44.3

%

Stock-based compensation - Subscriptions and services cost

300

242

361

Stock-based compensation - Products cost

1,074

963

756

Amortization of software development cost

1,256

864

272

Non-GAAP gross profit:

Subscriptions and services

76,973

75,084

57,217

Products

(1,675

)

(7,482

)

(3,101

)

Total Non-GAAP gross profit

$

75,298

$

67,602

$

54,116

Non-GAAP gross margin:

Subscriptions and services

85.4

%

84.0

%

83.1

%

Products

(2.8

)%

(14.4

)%

(6.2

)%

Total Non-GAAP gross margin

50.1

%

47.8

%

45.5

%

GAAP net income (loss)

$

14,877

$

5,764

$

(835

)

Stock-based compensation expense

19,734

17,200

17,012

Depreciation and amortization

1,697

1,345

829

Acquisition-related expense

1,329

—

—

Other operating expense

106

—

25

Gain on sale of long-term investment

(6,423

)

—

—

Interest income, net

(1,241

)

(1,284

)

(1,316

)

Other (income) expense, net

(70

)

(102

)

198

Provision for income taxes

415

339

502

Adjusted EBITDA

$

30,424

$

23,262

$

16,415

Adjusted EBITDA margin

20.2

%

16.5

%

13.8

%

  ARLO TECHNOLOGIES, INC.

RECONCILIATIONS OF GAAP MEASURES TO NON-GAAP MEASURES (UNAUDITED) (CONTINUED)

(In thousands, except percentage and per share data)

  Three Months Ended

March 29,
2026

December 31,
2025

March 30,
2025

GAAP net income (loss)

$

14,877

$

5,764

$

(835

)

Stock-based compensation expense

19,734

17,200

17,012

Gain on sale of long-term investment

(6,423

)

—

—

Others

2,776

949

297

Non-GAAP net income

$

30,964

$

23,913

$

16,474

GAAP earnings (loss) per share - basic

$

0.14

$

0.05

$

(0.01

)

Stock-based compensation expense

0.18

0.16

0.16

Gain on sale of long-term investment

(0.06

)

—

—

Others

0.02

0.01

—

Non-GAAP EPS - diluted

$

0.28

$

0.22

$

0.15

Weighted-average common shares outstanding:

Basic

106,995

105,434

102,217

Diluted

110,488

110,353

108,285

Free cash flow:

Net cash provided by operating activities

$

27,863

$

19,770

$

30,919

Less: purchases of property and equipment, including capitalized software

(2,419

)

(1,830

)

(2,803

)

Free cash flow (1)

$

25,444

$

17,940

$

28,116

Free cash flow margin (1)

16.9

%

12.7

%

23.6

%

ARLO TECHNOLOGIES, INC. SUPPLEMENTAL FINANCIAL INFORMATION (UNAUDITED)

(In thousands, except headcount and per share data)

  As of and for the three months ended

March 29,
2026

December 31,
2025

September 28,
2025

June 29,
2025

March 30,
2025

Cash, cash equivalents and short-term investments

$

167,498

$

166,425

$

165,544

$

160,401

$

153,106

Accounts receivable, net

$

52,174

$

39,666

$

76,698

$

61,450

$

46,054

Days sales outstanding

31

26

50

43

34

Inventories

$

43,958

$

41,185

$

44,371

$

30,877

$

34,559

Inventory turns

5.7

5.9

6.4

7.7

6.3

Weeks of channel inventory:

U.S. retail channel

13.2

10.1

12.5

12.5

12.8

U.S. distribution channel

9.5

3.0

5.5

11.0

12.6

APAC distribution channel

8.6

5.2

3.7

8.2

8.4

Deferred revenue

(current and non-current)

$

53,426

$

38,615

$

40,515

$

42,544

$

43,177

Cumulative registered accounts (1)

13,052

12,141

11,792

11,237

10,930

Cumulative paid accounts (2)

6,005

5,687

5,396

5,115

4,897

Annual recurring revenue (ARR) (3)

$

356,921

$

330,489

$

323,150

$

315,655

$

276,357

Headcount

369

376

374

382

369

Diluted shares

110,488

110,353

109,638

108,061

108,285

REVENUE BY GEOGRAPHY

(In thousands, except percentage data)

  Three Months Ended

March 29,
2026

December 31,
2025

March 30,
2025

Americas

$

83,986

55.9

%

$

103,910

73.5

%

$

70,097

58.9

%

EMEA

60,665

40.3

%

31,583

22.4

%

42,895

36.0

%

APAC

5,731

3.8

%

5,804

4.1

%

6,074

5.1

%

Total

$

150,382

100.0

%

$

141,297

100.0

%

$

119,066

100.0

%

More News From Arlo Technologies, Inc.

Arlo Technologies (ARLO - Free Report) reported $150.38 million in revenue for the quarter ended March 2026, representing a year-over-year increase of 26.3%. EPS of $0.28 for the same period compares to $0.15 a year ago.

The reported revenue represents a surprise of +7.99% over the Zacks Consensus Estimate of $139.25 million. With the consensus EPS estimate being $0.19, the EPS surprise was +47.37%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Arlo Technologies performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Non-GAAP gross margin - Subscriptions and services: 85.4% versus 83.8% estimated by two analysts on average.Non-GAAP gross margin - Products: -2.8% versus -14.5% estimated by two analysts on average.Revenue- Subscriptions and services: $90.1 million compared to the $87.6 million average estimate based on two analysts. The reported number represents a change of +30.9% year over year.Revenue- Products: $60.28 million compared to the $51.65 million average estimate based on two analysts. The reported number represents a change of +20.1% year over year.View all Key Company Metrics for Arlo Technologies here>>>

Shares of Arlo Technologies have returned +7.1% over the past month versus the Zacks S&P 500 composite's +11.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

2 hours ago

The Progressive Corporation $PGR Shares Sold by Woodley Farra Manion Portfolio Management Inc.Woodley Farra Manion Portfolio Management Inc. lowered its stake in The Progressive Corporation (NYSE:PGR - Free Report) by 2.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 305,408 shares of the insurance provider's

NYSE:PGR

Read The Progressive Corporation $PGR Shares Sold by Woodley Farra Manion Portfolio Management Inc.

2 hours ago

Woodley Farra Manion Portfolio Management Inc. Sells 16,282 Shares of The Walt Disney Company $DISMarketBeat

Woodley Farra Manion Portfolio Management Inc. cut its holdings in shares of The Walt Disney Company (NYSE:DIS - Free Report) by 2.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 708,928 shares of the entertainment gi

NYSE:DIS

Read Woodley Farra Manion Portfolio Management Inc. Sells 16,282 Shares of The Walt Disney Company $DIS

2 hours ago

Morgan Stanley $MS Stock Position Cut by Woodley Farra Manion Portfolio Management Inc.MarketBeat

Woodley Farra Manion Portfolio Management Inc. cut its holdings in shares of Morgan Stanley (NYSE:MS - Free Report) by 2.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 556,628 shares of the financial servi

NYSE:MS

Read Morgan Stanley $MS Stock Position Cut by Woodley Farra Manion Portfolio Management Inc.

2 hours ago

Xponance LLC Grows Position in Texas Instruments Incorporated $TXNMarketBeat

Xponance LLC grew its position in shares of Texas Instruments Incorporated (NASDAQ:TXN - Free Report) by 7.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 177,875 shares of the semiconductor company's stock after purchas

NASDAQ:TXN

Read Xponance LLC Grows Position in Texas Instruments Incorporated $TXN

2 hours ago

Xponance LLC Acquires 152,351 Shares of AT&T Inc. $TMarketBeat

Xponance LLC increased its holdings in shares of AT&T Inc. (NYSE:T - Free Report) by 14.4% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,213,315 shares of the technology company's stock after purchasing an additional 152,

NYSE:T

Read Xponance LLC Acquires 152,351 Shares of AT&T Inc. $T

Sort By

Time Frame

Alert Type

Keywords

Page 1 of 320

I used to think the biggest opportunities in tech were hiding inside flashy artificial intelligence (AI) models or chip companies. I've spent a lot of time over the last couple of years chasing beaten-down big-name stocks, but sometimes the more interesting story is a business quietly transforming its products and subscription model right under Wall Street's nose -- and both Arlo Technologies (ARLO +3.17%) and Evolv Technologies (EVLV +5.14%) look like companies the market still fundamentally misunderstands.

Image source: Getty Images.

Arlo Technologies is not a camera company anymore This is the part Wall Street keeps getting wrong about Arlo Technologies: It still prices the stock like a consumer hardware business, even as the company has spent the last two years systematically converting itself into a pure software and services platform.

The camera hardware still exists, but it's increasingly just the vehicle that gets subscribers into Arlo's ecosystem. The real product is Arlo Intelligence -- a suite of AI features baked into the subscription platform that handles everything from package detection and person recognition to proactive security alerts that the company describes as moving beyond passive recording into automated, real-time response. Arlo isn't just storing video anymore. It's interpreting what's happening in front of the camera and deciding what matters.

What changed the story for me is the partnership strategy. In January, Arlo extended its relationship with Samsung in a service-only arrangement -- no hardware required -- to power smart security features inside Samsung SmartThings for millions of connected home users. That's a clean departure from selling cameras. It's licensing AI software to one of the world's largest consumer electronics platforms.

The market is still sitting on its hands. Some fair-value estimates on Arlo sit at $24 against a current price of around $13.50. Analysts covering the stock have an average price target of $22. The stock is down on a one-month basis, even as the business has turned profitable and annual recurring revenue is growing at a 28% clip. That's a gap between what the business is doing and what the market is crediting it for -- and such gaps tend to close over time.

Today's Change

(

3.17

%) $

0.39

Current Price

$

12.71

Evolv Technologies is winning the venues, and Wall Street still isn't paying attention Evolv Technologies (EVLV +5.14%) makes AI-powered weapons detection systems. Not drones or security towers, but scanners that use machine learning to identify concealed guns and knives without requiring people to stop, empty their pockets, or wait in slow security lines. Every major sports venue, arena, or school that replaces traditional security technology and metal detectors with Evolv's system is signing a subscription contract that is likely to be renewed and expanded over time.

Today's Change

(

5.14

%) $

0.30

Current Price

$

6.14

The company has been stacking those contracts, and its pace hasn't slowed. In March, the Houston Astros renewed and expanded their partnership with Evolv to cover all fan entry points at Minute Maid Park. In April, Crypto.com Arena -- home of the NBA's Los Angeles Lakers and the NHL's Los Angeles Kings -- renewed and expanded its multiyear partnership. Later that month, Evolv reached 50% market share across all North American professional soccer venues after adding the Philadelphia Union to its roster. This is a pattern of the same customers coming back and asking for more.

The professional sports use case gets the headlines, but the deployment that I think is most underappreciated is in educational settings. In 2025, after Evolv reached a settlement with the Federal Trade Commission over what the regulator asserted were deceptive marketing claims, there was a window for some of the company's school customers to cancel their contracts -- but 92% of eligible K-12 customers chose to stay. That retention number, coming immediately after a regulatory challenge, tells you more about the product's actual value to customers than any press release would.

In my opinion, Wall Street is treating Evolv like a speculative security start-up that still needs to prove its model. However, the company's recurring contract structure, its retention rate, and its expansion pattern across professional sports, entertainment, and education suggest the model is proven. To me, that's the definition of a discount worth buying.

MCLEAN, Va.--(BUSINESS WIRE)--Booz Allen Hamilton Holding Corporation (NYSE: BAH), the parent company of advanced technology company Booz Allen Hamilton Inc., today announced preliminary results for the fourth quarter and full fiscal year 2026.

"We enter FY27 with momentum and are well-positioned for the year ahead," said Horacio Rozanski, Booz Allen Chairman and CEO. "We’re investing in proven growth areas and building tech to create long-term value for our shareholders and our nation.”

Share Booz Allen’s press release is available at:
newsroom.boozallen.com
investors.boozallen.com

Booz Allen’s earnings presentation is available at investors.boozallen.com.

Booz Allen will host a conference call at 8 a.m. EDT on Friday, May 22, 2026, to discuss its financial results. Analysts and institutional investors may participate by registering online at investors.boozallen.com. Participants are requested to register a minimum of 15 minutes before the start of the call.

The conference call will be webcast simultaneously to the public through a link at investors.boozallen.com. A replay of the conference call will also be available on the site beginning at 11 a.m. EDT on Friday, May 22, 2026, and continuing for 12 months.

About Booz Allen Hamilton

Booz Allen is an advanced technology company delivering outcomes with speed for America’s most critical defense, civil, and national security priorities. We build technology solutions using AI, cyber, and other cutting-edge technologies to advance and protect the nation and its citizens. By focusing on outcomes, we enable our people, clients, and their missions to succeed—accelerating the nation to realize our purpose: Empower People to Change the World®.

With global headquarters in McLean, Virginia, our company employs approximately 31,500 people globally as of March 31, 2026, and had revenue of $11.2 billion for the 12 months ended March 31, 2026. To learn more, visit www.boozallen.com. (NYSE: BAH)

BAHPR-FI

Booz Allen Hamilton reported higher fiscal fourth-quarter profit as its cost-cutting initiatives helped to offset declines in revenue.

The Pentagon's AI Pivot Supercharges Defense StocksBooz Allen Hamilton NYSE: BAH executives said the government technology contractor exited what Chief Executive Horacio Rozanski called its “most challenging year” as a public company with stronger profitability than expected, even as revenue declined because of weakness in its civil business.

On the company’s fiscal fourth-quarter 2026 earnings call, Rozanski said Booz Allen faced “unprecedented headwinds” in civil work and significant changes across its markets, but responded through cost discipline, contract execution and continued investment in cyber, defense technology and artificial intelligence. He said the company is entering fiscal 2027 with “both momentum and focus,” while acknowledging continued uncertainty as federal customers adjust procurement approaches.

Get Booz Allen Hamilton alerts:

Catching Falling Knives: Is It Time to Buy These Beaten-Down Stocks?“Despite declining revenue, profitability exceeded our revised expectations,” Rozanski said. “What’s particularly notable is that we delivered this bottom-line performance while continuing to invest for future growth.”

Revenue Declines, But Profitability Tops Expectations Chief Financial Officer Troy Lahr, who joined Booz Allen earlier this month, said fiscal 2026 gross revenue was $11.2 billion, with the year-over-year decline driven by the company’s civil business. Adjusted EBITDA was $1.2 billion, with an adjusted margin of 11%, and adjusted diluted earnings per share were $6.51. Free cash flow totaled $951 million.

Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH StockFor the fourth quarter, revenue declined 6.4% year over year to $2.8 billion. Revenue excluding billable expenses fell approximately 7% from the prior-year period. Lahr said the national security portfolio grew 1.6% year over year in the quarter, supported by demand for intelligence work and partially offset by lower billable expenses for defense customers. Civil revenue declined 23% year over year, which he attributed to the roll-off of the PTEMS contract and reductions on other contracts.

Adjusted EBITDA in the quarter was $309 million, with an adjusted EBITDA margin of 11.1%, up 50 basis points from a year earlier. Adjusted diluted EPS rose roughly 11% year over year to $1.78. Lahr said the increase reflected stronger profitability, a lower tax rate, a reduced share count and $12 million of pre-tax unrealized gains tied to Booz Allen’s ventures portfolio.

Net bookings in the quarter were $2.5 billion, producing a quarterly book-to-bill ratio of 0.9 times and a trailing 12-month book-to-bill ratio of 1.1 times. Backlog ended the fiscal year at $38 billion, up about 3% year over year. Funded backlog increased sequentially to $4.3 billion.

Fiscal 2027 Guidance Calls for Uneven Recovery For fiscal 2027, Booz Allen guided for revenue of $11.2 billion to $11.7 billion. Lahr said recent divestitures and acquisitions are expected to roughly offset each other. The company expects its national security portfolio to grow in the mid-single digits, while civil revenue is projected to decline in the high single digits as the business works through difficult comparisons, particularly in the first half of the year.

Lahr said the first quarter is expected to be the “low point for growth,” with sequential improvement through the year. Adjusted EBITDA is expected to range from $1.24 billion to $1.29 billion, implying an adjusted EBITDA margin of about 11%. Adjusted EPS is expected to be between $6.00 and $6.35. Free cash flow is forecast at $825 million to $925 million, including estimated fiscal 2027 expenditures for the company’s new Reston headquarters. The guidance excludes a previously disclosed $170 million IRS refund, which Lahr said is now expected in fiscal 2028.

During the question-and-answer portion, Lahr said the guidance reflects what Booz Allen sees in the market today and does not assume “edge cases.” Rozanski added that the company is operating in a fluid environment, including potential budget uncertainty tied to an election year.

Civil Business Remains Under Pressure President and Chief Operating Officer Kristine Martin Anderson said Booz Allen’s civil and national security markets remain “bifurcated,” with different near-term dynamics. Civil demand remains below historical levels, but she said the company is seeing acceleration, including a fourth-quarter civil book-to-bill of 1.2 times led by the health business.

Martin Anderson said the volume of civil awards is high, but many recompetes are coming with shorter periods of performance and smaller scopes. She said this means it will take time for improved demand to translate into growth. The business also faces difficult comparisons tied to last year’s contract cuts and reductions in work at Treasury.

In response to an analyst question, Martin Anderson said the company is seeing headwinds from prior-year contract reductions, Treasury-related reductions, smaller recompetes, fewer new starts because of last year’s weak award environment and budget challenges at the Department of Homeland Security. She also cited tailwinds including recent wins, an expanding customer base, a larger pipeline and strong recompete win rates.

Rozanski said Booz Allen is in “close contact” with customers and has had productive conversations following reputational issues raised by an analyst. “We are letting our work speak for itself,” he said, adding that even at Treasury the company is looking for opportunities to “turn the page.”

National Security, Cyber and Defense Tech Drive Optimism Executives repeatedly pointed to national security, cyber and defense technology as the main growth drivers for fiscal 2027 and beyond. Martin Anderson said Booz Allen won $1.7 billion of national security work in the fourth quarter and is well positioned against priorities including cyber and defense tech.

She highlighted increasing demand for AI-enabled cyber solutions, saying Booz Allen supports important cyber missions in national security, defends federal agencies from cyberattacks, serves Fortune 500 companies across all 16 critical infrastructure areas and responds to more than 1,000 cyber incidents a year.

Rozanski said cyber demand is expected to accelerate across national security, civil and commercial markets. He said offensive cyber tools are becoming agentic faster than defensive tools, creating a need for Booz Allen’s cyber offerings, including its Vellox suite. The company is accelerating the release schedule for multiple Vellox products because “the demand is now,” he said.

Martin Anderson also cited Booz Allen’s award of an other transaction authority contract on Golden Dome for America’s Space-Based Interceptor program and the fourth-quarter award of Breakthrough Engineering and Advanced Technology Solutions, or BEATS, a $937 million single-award engineering and technology contract supporting Army modernization priorities.

Procurement Shift and Capital Deployment Rozanski said Booz Allen is preparing for a market in which federal customers buy differently, with more emphasis on speed, commercial solutions and accountability for outcomes. He said the company drove a nearly 90% increase in OTA proposal submissions and about a 50% increase in OTA awards from the prior year.

He said Booz Allen expects productivity gains over time from delayering, “agentifying” its business, moving toward outcome-based and fixed-price work, and monetizing intellectual property. He said those trends should eventually cause revenue growth to outpace headcount growth, and profit growth to outpace revenue growth.

Lahr said Booz Allen deployed $366 million of capital in the fourth quarter, including $219 million in strategic investments through Booz Allen Ventures and venture partnerships, and $147 million in dividends and share repurchases. The company ended the quarter with $728 million in cash, total liquidity of $2.2 billion and a net leverage ratio of 2.6 times trailing 12-month adjusted EBITDA.

Rozanski closed the call by saying Booz Allen is focused on returning to growth while investing in cyber, defense technology, AI, quantum, 6G and related areas. “We’re moving faster, we’re investing with focus, and we’re building the technologies that make America safer and stronger,” he said.

About Booz Allen Hamilton NYSE: BAHBooz Allen Hamilton Holding Corporation is a publicly traded management and technology consulting firm headquartered in McLean, Virginia. The company provides a wide range of professional services and solutions in strategy, analytics, digital transformation, engineering and cyber security. Its expertise spans from supporting federal civilian agencies to defense, intelligence and homeland security organizations, as well as select commercial industries.

Key offerings include data analytics and artificial intelligence applications, software development and modernization, systems integration, and cyber risk management.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in Booz Allen Hamilton Right Now?Before you consider Booz Allen Hamilton, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Booz Allen Hamilton wasn't on the list.

While Booz Allen Hamilton currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Booz Allen Hamilton Holding Corporation (BAH) Q4 2026 Earnings Call Transcript